Loading
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Previous close
$34.21
−$0.54 · -1.55%
After-hours
$34.21
$0.00 · 0.00%
Oct 8, 7:35 PM ET
Regular session · ET · Market data may be delayed.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Day range
Current $34.21
52-week range
Current $34.21
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
4
Overpriced
Sentiment
59
Mixed
Risk
27
Moderate Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Day range
Current $34.21
52-week range
Current $34.21
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 8.26M USD | 29.05M USD | 32.71M USD | 31.53M USD | 55.29M USD |
| Cost of goods sold | 1.29M USD | 911K USD | 1.6M USD | 3.03M USD | 8.97M USD |
| Gross profit | 6.98M USD | 28.14M USD | 31.11M USD | 28.5M USD | 46.32M USD |
| Research and development | 681.81M USD | 550.41M USD | 439.91M USD | 454.06M USD | 483.04M USD |
| Selling, general, and administrative | 610.47M USD | 591.41M USD | 416.13M USD | 383.45M USD | 775.03M USD |
| Operating expenses | 1.29B USD | 1.14B USD | 856.04M USD | 837.51M USD | 1.26B USD |
| Interest income | 178.11M USD | 258.38M USD | 146.43M USD | 32.18M USD | 369K USD |
| Interest expense | — | — | 34.78M USD | 27.97M USD | 7.04M USD |
| Depreciation and amortization | 3.35M USD | 14.07M USD | 22.04M USD | 18.86M USD | 5.93M USD |
| Operating income | −1.29B USD | −1.11B USD | −824.93M USD | −809.01M USD | −1.21B USD |
| Net income | −299.77M USD | −171.98M USD | 4.35B USD | −1.01B USD | −845.26M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$46.75
36.66% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI554.94M0.02%2.3T USD0.03%$379.56-0.39%
Vanguard Morningstar Small-Cap ETFVB401.32M0.21%185.3B USD0.03%$287.63+0.23%
Invesco S&P MidCap Momentum ETFXMMO239.95M3.39%7.08B USD0.34%$147.38-0.63%
Vanguard Morningstar Small-Cap Growth ETFVBK230.3M0.50%44.7B USD0.05%$340.59-0.48%
Vanguard Extended Market ETFVXF181.43M0.19%95.4B USD0.05%$233.13-0.15%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY142.57M0.55%25.53B USD0.23%$666.26+0.35%
iShares Biotechnology ETFIBB137.8M1.32%10.41B USD0.44%$200.48-1.41%
State Street SPDR S&P Biotech ETFXBI126.23M1.25%10.11B USD0.35%$149.29-0.63%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Momentum ETFXMMOVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P MIDCAP 400 ETF TrustMDYiShares Biotechnology ETFIBBState Street SPDR S&P Biotech ETFXBIAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
